HAVCR2 (Sabatolimab Biosimilar) Recombinant Monoclonal Antibody

1. TIM-3 expression was predominantly localized to myeloid cells in both human and murine tumors PMID:29316433
2. TIM-3 and IL-37 may be used as potential biomarkers of active rheumatoid arthritis. PMID:30106887
3. High TIM3 expression is associated with gastric cancer. PMID:30106451
4. miR-498 can effectively suppress TIM-3 expression in the acute myeloid leukemia cell line PMID:30107988
5. These results indicate that TIM-3 may be involved in the pathogenesis of immune thrombocytopenia which subsequently can represent an opportunity for new therapeutic plan, moreover. This may have a prognostic value for disease severity. PMID:28974109
6. Within many tumors, PD-1/Tim-3 coexpressing CD8-T cells lose their ability to secrete cytokines and their intratumoral infiltration correlates with a bad prognosis. Tim-3 appeared as a potential biomarker of anti-PD-1 resistance. Combined blockade of PD-1 and Tim-3 axis demonstrated potent clinical efficacy in preclinical models and reinforced the rationale of using an anti-Tim-3 to override tumor resistance.[review] PMID:29547109
7. this study shows that TIM-3 expression identifies a distinctive PD-1(+) follicular helper T cell subset, with reduced interleukin 21 production and B cell help function in ovarian cancer patients PMID:29482158
8. TIM-3 high expression rate was an independent prognostic factor for extranodal NK/T cell lymphoma, nasal type PMID:28901003
9. sTim-3 is a promising biomarker for allograft dysfunction, but unable to differentiate allograft rejection from other causes of renal dysfunction in kidney transplantation recipients PMID:29310109
10. The expression of Tim-3 on CD14+ monocytes is involved in systemic inflammatory reaction after intracerebral hemorrhage. PMID:29310959
11. TIM-3 gene may play an important role as a genetic risk factor for the progression and prognosis of invasive breast cancer. PMID:29263040
12. Tim-3(+) NK cells had decreased capability of IFN-r secretion, while Tim-3(+) monocytes showed a M2-like phenotype. Importantly, Tim-3 level on both NK cells and monocytes positively correlated with the ratio of Ki-67(+) tumor cells. PMID:29174343
13. T-cell immunoglobulin mucin-3/galectin-9 (Tim-3/Gal-9) binding signaling can also engage other binding partners to induce distinct cellular responses [Review]. PMID:29027155
14. Polymorphism +4259A>C in exon 3 of the TIM-3 gene is associated with susceptibility to multiple sclerosis but polymorphism -1637C>T in the promoter region of TIM-1 is not. PMID:29141799
15. The interaction between Gal-9/TIM-3 pathway and follicular helper cells contributed to viral persistent in chronic hepatitis C virus infection. PMID:28772217
16. Exosomal total protein, Tim-3 and Galectin-9 were up-regulated in non-small cell lung cancer plasma. PMID:29452091
17. the monitoring of sTim3 in urine may be a novel and promising noninvasive approach for the detection of AR. Furthermore, measurement of sTim3 in urine may contribute to predict the response to antirejection therapy and a poor outcome following AR. PMID:28586044
18. the CD4(+)CD25(+)Foxp3(+) Treg cells from RA patients demonstrated a reduction of Tim3 and were less functional than Treg cells from healthy controls in a Tim3-related manner. PMID:28478516
19. our study highlights the role of TIM-3 as a potential prognostic marker and a promising therapeutic target in solid tumors. PMID:28423646
20. HAVCR2 regulates cytokines, chemokines, prostaglandins and cell adhesion molecules in the presence of viral infection, which suggests a potential for HAVCR2 activators as therapeutics for the management of preterm birth associated with viral infections. PMID:28466996
21. serum levels may be increased in patients with early phase diffuse cutaneous systemic sclerosis and associated with cardiac involvement and renal crisis PMID:27651303
22. Preoperative Tim3 expression on peripheral NK cells is correlated with differential staging in colorectal cancer, and may be useful as a serum biomarker. PMID:28440449
23. TIM-3 polymorphism is associated with response to therapy in hepatitis B virus-related hepatocellular carcinoma. PMID:27034168
24. BMI-1, TIM-3 and CLL-1 have roles in acute myeloid leukemia prognosis and therapy PMID:27506934
25. Quantification of TIM-3 and KIM-1 mRNA expressions, along with KIM-1 protein measurements in urine and blood could be employed as promising tools for noninvasive diagnosis of allograft dysfunction. PMID:28757398
26. Results show that human acute myeloid leukemia (AML) cells possess a secretory pathway which leads to the production and release of soluble Tim-3 and galectin-9. Both proteins prevent the activation of NK cells and impair their AML cell-killing activity. PMID:28750861
27. after 14 days of glucocorticoid therapy, clinical findings (serum bilirubin, skin GVHD) and plasma biomarkers (TIM3, ST2, sTNFR1) can predict failure of GVHD treatment and nonrelapse mortality. PMID:28478120
28. These findings suggested that rs10053538 in TIM-3 might increase susceptibility to and promote the progression of breast cancer in Chinese women PMID:27248321
29. Results indicate that T cell Ig and mucin domain 3 protein (TIM-3) polymorphisms (-1516G/T, -574G/T, and +4259T/G) were associated with the increased risk of cancer in Chinese Han population. PMID:27008699
30. In cultured MART1-specific CD8 T cells stimulated with peptide-loaded artificial antigen-presenting cells, anti-TIM-3 antibody treatment promotes generation of effector T cells, with acquisition of an activated phenotype, increased cytokine production, enhanced proliferation, and a transcription program associated with T cell differentiation. Anti-TIM-3 drives CD8 T cell differentiation through activation of mTORC1. PMID:29127145
31. Our results show that Tim-3 is a critical negative regulator of NLRP3 inflammasome and provides a potential target for intervention of diseases with uncontrolled inflammasome activation. PMID:28799242
32. soluble Tim-3 might play inhibitory roles in impaired Tim-3-mediated clearance of apoptotic cells in systemic lupus erythematosus. PMID:28754800
33. We found a novel mechanism through which Tim-3 could suppress antitumor immunity by utilizing the suppression of CD4(+) follicular helper cells (Tfh) function and provide new insight in the regulation of Tfh cells in breast cancer patients PMID:27156907
34. Tim3/Gal-9 alleviates the inflammation of TAO patients via suppressing Akt/NF-kappaB signaling pathway. PMID:28756232
35. this study shows that severe aplastic anemia untreated patients have lower TIM-3 expression on NK cells and CD56dim NK subsets compared with normal controls, and are correlated with the severity of pancytopenia of SAA PMID:28637584
36. We conclude that Tim-3 is a biomarker of dysfunctional plasmacytoid dendritic cells PMID:28264968
37. The present study defines the minimal TIM-3 promoter region and demonstrates its interaction with c-Jun during TIM-3 transcription in CD4(+) T cells. PMID:27243212
38. Our findings establish intratumoral Tim-3(+)PD1(+)CD8(+) T cells as critical mediators of an aggressive phenotype in RCC. PMID:27872087
39. Osteosarcoma patients with higher Tim-3 had relatively lower survival. Multivariate analyses for overall survival revealed that high serum soluble Tim-3 level was an independent prognostic factor for osteosarcoma PMID:28671022
40. urther analyses revealed that the levels of Tim-3 on CD4+ T cells and CD8+ T cells exhibited different expression patterns in terms of localization depending on pathological category of prostate cancer and metastasis. Immunohistochemical analysis revealed that positive staining of Tim-3 in prostate cancer but little or no staining of Tim-3 was observed in benign prostate hyperplasia epithelium. PMID:28681697
41. this review discusses the recent findings on Tim-3, the role it plays in regulating immune responses in different cell types and the rationale for targeting Tim-3 for effective cancer immunotherapy PMID:28258697
42. The -1516G > T, -574G > T and +4259T > G SNPs within TIM-3 gene might play an important role as a genetic risk factor in the pathogenesis of ET. PMID:27990849
43. this study shows that that Tim-3 expression defines a subpopulation of PD-1+ exhausted NY-ESO-1-specific CD8+ T cell and PD-1+Tim-3+ CD8+ T cells represented the largest subset of NY-ESO-1-specific CD8+ T cells in gastric cancer patients PMID:28110884
44. Increased TIM3+CD8+T cells with lower perforin and granzyme B expression and higher CD95 expression in MDS patients had been observed. These findings suggested that TIM3 might be related to CD8+T cells defect. PMID:27846431
45. our results suggested that PD-1 and TIM-3 blockade might be necessary in developing effective immunotherapeutic strategies in malignant Schwannoma, in which TIM-3 may play a more important role. PMID:28475007
46. these data suggest that the high Tim-3 expression in monocytes could be utilized by tumor-promoting Gal-9 expression on CD4(+) T cells PMID:28466780
47. In conclusion, Tim-3 on immune cells negatively regulates cell-mediated immunity against Plasmodium infection, and blocking Tim-3 signaling enhances sterile immunity and may play a protective role during malarial parasite infections. PMID:27638944
48. this study shows that the transcription factor T-bet controls Tim-3-mediated inhibition of monocyte/macrophage function during chronic hepatitis C virus infection PMID:27809352
49. this study shows that TIM-3 expressed on myeloid leukaemia cells may facilitate functional exhaustion in T helper cells PMID:27565576
50. this study shows that in osteosarcoma patients, Tim3 expression did not directly mediate immune suppression, but the interaction between Tim3+ T cells and monocytes, naive CD4+ T cells, and Gal9-expressing CD4+ CD25+ Tregs could resulting in progressive suppression of Th1 responses PMID:28103502

Show More

Hide All

HGNC: 18437

UNIGENE: Hs.710500

KEGG: hsa:84868

STRING: 9606.ENSP00000312002

OMIM: 606652